Yasmin Schmid

Senior Attending Physician at University Hospital Basel

Data updated

Papers

26 publications

Trials

0 clinical trials

Research Footprint

Yasmin Schmid appears in 26 tracked papers (2013–2026), most studied alongside LSD, MDMA and Psilocybin, across Healthy Volunteers, Anxiety Disorders and Medicinal Chemistry & Drug Development.

Most-cited paper: Acute effects of lysergic acid diethylamide in healthy subjects (424 citations).

Frequent co-authors: Matthias Liechti, Patrick Dolder and Stefan Borgwardt.

Background & Research

Dr. Yasmin Schmid is a leading expert in the clinical pharmacology of serotonergic psychedelics. Her research at the University of Basel characterizes the acute and long-lasting effects of LSD and MDMA in both healthy volunteers and patients. She focus on the safety, efficacy, and neurobiological mechanisms that underpin the therapeutic potential of these substances in palliative care and psychiatry.

Key Impact

Clinical pharmacologist specializing in the safety and dose-response profiles of LSD and MDMA.

26

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

33 collaborators· click a node to visit their profile

Full network →

Compounds

LSDMDMAPsilocybinMescalinePlacebo

Topics

Healthy VolunteersAnxiety DisordersMedicinal Chemistry & Drug DevelopmentDepressive DisordersInterpersonal Functioning & Social ConnectednessPersonality & Trait FactorsPTSDMajor Depressive Disorder (MDD)Neuroimaging & Brain MeasuresSubstance Use Disorders (SUD)Palliative & End-of-Life DistressOlder AdultsSet & SettingPublic Health, Prevention & Behaviour ChangeHeadache Disorders (Cluster & Migraine)Chronic PainSchizophreniaObsessive-Compulsive Disorder (OCD)AdolescentsTobacco/Nicotine Use Disorder (TUD)Equity and EthicsMicrodosingSafety & Risk Management

Top Collaborators

Affiliations

Institutions, companies, and organisations Yasmin Schmid is associated with.

University of Basel

academic

The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.

View stakeholder →